ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMLN Stock Price » AMLN Stock News

Amylin Pharmaceuticals Share News

Amylin Pharmaceuticals (mm) Stock Price
AMLN Stock Price		 Amylin Pharmaceuticals (mm) Stock Chart
AMLN Stock Chart		 Amylin Pharmaceuticals (mm) Stock News
AMLN Stock News
Amylin Pharmaceuticals (mm) Company Information
AMLN Company Information		 Amylin Pharmaceuticals (mm) Stock Trades
AMLN Stock Trades

Amylin is Said To Draw First-Round Bids of Up to $29/Share -Bloomberg

DOW JONES NEWSWIRES Diabetes drug maker Amylin Pharmaceuticals Inc. (AMLN) drew four first-round bids valuing the company at $25 to $29 a share, with Pfizer Inc. (PFE) dropping out of the process, Bloomberg News reported Monday on its website, citing people with knowledge of the process. AstraZeneca Plc (AZN), Sanofi (SNY), Merck & Co. (MRK) and Bristol-Myers Squibb Co. (BMY) submitted offers, with revised offers due by the end of the month and a sale likely in July, two people told Bloomberg. Representatives for Amylin, Merck, Bristol-Myers, AstraZeneca, Sanofi and Pfizer declined comment to Bloomberg. Full story at: www.bloomberg.com/news/2012-06-04/amylin-said-to-draw-bids-of-25-to-29-a-share-in-first-round.html -Dow Jones Newswires; 212-416-2900

Stock News for Amylin Pharmaceuticals (AMLN)
DateTimeHeadline
08/09/201208:24:09AstraZeneca: Bristol-Myers Squibb Completes Purchase of Amylin
08/02/201212:30:06Bristol-Myers Executive Charged With Insider Trading
08/02/201212:17:26U.S. Charges Bristol-Myers Executive With Insider Trading
08/02/201211:07:11Bristol-Myers Pension Executive Robert Ramnarine Arrested for...
07/26/201210:24:24Evercore 2nd-Quarter Profit Climbs 19% On Higher Investment Banking...
07/25/201208:20:16Bristol-Myers Profit Falls 28%
07/25/201208:00:01Bristol-Myers 2nd-Quarter Profit Falls 28% on Drug-Patent Expirations
07/02/201211:53:36Bristol Sees Commercial Muscle Accelerating Sales of Bydureon
06/29/201223:36:26Bristol-Myers to Buy Amylin Pharmaceuticals for $5.3 Billion
06/10/201220:35:15Novo Nordisk's Victoza More Efficient Than Peers In New Study
06/09/201208:30:11Sanofi's Lantus Cuts Blood Sugar More Than Merck's Januvia in...
06/05/201209:10:47Amylin is Said To Draw First-Round Bids of Up to $29/Share -Bloomberg
04/25/201214:53:05Icahn: Suit Against Amylin Dropped After Talks With CEO
04/19/201213:53:31FDA Is Asked To Remove Novo Nordisk Diabetes Drug From Market
04/09/201213:08:09Icahn Files Lawsuit Against Amylin To Force Nomination Extension
03/28/201210:08:30Amylin Has Rejected $3.5 Billion Buyout Bid By Bristol-Myers...
03/23/201209:08:11Amylin: EU Approves Diabetes Treatment Byetta With Basal Insulin
01/30/201217:42:15US Stocks Edge Lower As Europe's Debt Flashpoints Weigh
01/30/201208:02:33US Stock Futures Lower On Renewed Worries Over Greece
01/27/201216:12:26FDA Approves Amylin's Bydureon Diabetes Drug After Delays

Amylin Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad